Changes in PPAR gene expression and myocardial tolerance to ischaemia: Relevance to pleiotropic effects of statins

Canadian Journal of Physiology and Pharmacology

Volumn 87, Issue 12, 2009, Pages 1028-1036

  Ravingerová, Táňa ^a   Adameová, Adriana ^b   Kelly, Tara ^c   Antonopoulou, Efthymia ^c   Pancza, Dezider ^a   Ondrejčáková, Mária ^a,d   Khandelwal, Vinoth Kumar Megraj ^a,e   Čarnická, Slávka ^a   Lazou, Antigone ^c  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b Physics and Informatics   (Slovakia)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^e M S UNIVERSITY OF BARODA   (India)

Author keywords

Myocardial ischaemia; PPAR; Rat heart; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SIMVASTATIN; TRIPHENYLTETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HEART ARRHYTHMIA; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; ISOLATED HEART; MALE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; RAT;

ANIMALS; ARRHYTHMIAS, CARDIAC; CHOLESTEROL; GENE EXPRESSION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOBLOTTING; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIMVASTATIN;

EID: 76549098871     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y09-071     Document Type: Conference Paper

References (47)

1. Adameová, A., Kuzelová, M., Faberová, V., and Svec, P. 2006. Protective effect of sirnvastatin and VULM 1457 in ischaemic-reperfused myocardium of the diabetic-hypercholesterolemic rats. Pharmazie, 61(9): 807-808. PMID:17020164.
2. Barger, P.M., and Kelly, D.P. 2000. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc. Med. 10(6): 238-245. doi: 10.1016/S1050-1738(00)00077-3. PMID:11282301.
3. Barger, P.M., Brandt, J.M., Leone, T.C., Weinheimer, C.J., and Kelly, D.P. 2000. Deactivation of peroxisome proliferator-activated receptor-α during cardiac hypertrophic growth. J. Clin. Invest. 105(12): 1723-1730. doi:10.1172/JCI9056. PMID:10862787.
4. Bell, R.M., and Yellon, D.M. 2003. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J. Am. Coll. Cardiol. 41(3): 508-515. doi:10.1016/S0735-1097(02)02816-4. PMID:12575984.
5. Braissant, O., Foufelle, F., Scotto, C., Dauça, M., and Wahli, W. 1996. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology, 137(1): 354-366. doi:10.1210/en.137.1.354. PMID:8536636.
6. Chen, J., Nagasawa, Y., Zhu, B.M., Ohmori, M., Harada, K., Fujimura, A., and Hashimoto, K. 2003. Pravastatin prevents arrhythmias induced by coronary artery ischemia/reperfusion in anesthetized normocholesterolemic rats. J. Pharmacol. Sci. 93(1): 87-94. doi: 10.1254/jphs.93.87. PMID:14501157.
7. Curtis, M.J. 1998. Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced ventricular fibrillation. Cardiovasc. Res. 39(1): 194-215. doi: 10.1016/S0008-6363(98)00083-2. PMID:9764200.
8. D'Annunzio, V., Donato, M., Erni, L., Miksztowicz, V., Buchholz, B., Carrión, C.L., et al. 2009. Rosuvastatin given during reperfusion decreases infarct size and inhibits matrix metalloproteinase-2 activity in normocholesterolemic and hypercholesterolemic rabbits. J. Cardiovasc. Pharmacol. 53(2): 137-144. doi: 10.1097/FJC.0b013e318197c5e9. PMID:19188835.
9. Delerive, P., Fruchart, J.C., and Staels, B. 2001. Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 169(3): 453-459. doi:10.1677/joe.0.1690453. PMID:11375115.
10. Desvergne, B., and Wahli, W. 1999. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20(5): 649-688. doi:10.1210/er.20.5.649. PMID:10529898.
11. Di Napoli, P., Antonio Taccardi, A., Grilli, A., Spina, R., Felaco, M., Barsotti, A., and De Caterina, R. 2001. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc. Res. 51(2): 283-293. doi: 10.1016/S0008-6363(01)00306-6. PMID:11470468.
12. Efthymiou, C.A., Mocanu, M.M., and Yellon, D.M. 2005. Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. J. Cardiovasc. Pharmacol. 45(3): 247-252. doi: 10.1097/01.fjc.0000154376.82445.06. PMID:15725950.
13. Escher, P., Braissant, O., Basu-Modak, S., Michalik, L., Wahli, W., and Desvergne, B. 2001. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology, 142(10): 4195-4202. doi: 10.1210/en.142.10.4195. PMID:11564675.
14. Fragasso, G., Piatti Md, P.M., Monti, L., Palloshi, A., Setola, E., Puccetti. P., et al. 2003. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am. Heart J. 146(5): E18. doi: 10.1016/S0002-8703(03)00415-0. PMID:14597947.
15. Gilde, A.J., van der Lee, K.A., Willemsen, P.H., Chinetti, G., van der Leij, F.R., van der Vusse, G.J., et al. 2003. Peroxisome proliferator-activated receptor (PPAR) α and PPARβ/δ, but not PPARγ, modulate the expression of genes involved in cardiac lipid metabolism. Circ. Res. 92(5): 518-524. doi: 10.1161/01.RES.0000060700.55247.7C. PMID:12600885.
16. Hall, G., Hasday, J.D., and Rogers, T.B. 2006. Regulating the regulator: NP-κB signaling in heart. J. Mol. Cell. Cardiol. 41(4): 580-591. doi:10.1016/j.yjmcc.2006.07.006. PMID:16949095.
17. Huss, J.M., and Kelly, D.P. 2004. Nuclear receptor signaling and cardiac energetics. Circ. Res. 95(6): 568-578. doi:10.1161/01.RES.0000141774. 29937.e3. PMID:15375023.
18. Ikeda, Y., Young, L.H., and Lefer, A.M. 2003. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myucardium in normochulesterolemic rats. J. Cardiovasc. Pharmacol. 41(4): 649-656. doi: 10.1097/00005344-200304000-00019. PMID:12658068.
19. Kantor, P.F., Lucien, A., Kozak. R., and Lopaschuk, G.D. 2000. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 86(5): 580-588. PMID:10720420.
20. Kliewer, S.A., Xu, H.E., Lambert, M.H., and Willson, T.M. 2001. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog. Horm. Res. 56(1): 239-263. doi:10.1210/rp.56.1.239. PMID:11237216.
21. Li, C., Browder, W., and Kao, R.L. 1999. Early activation of transcription factor NP-κB during ischemia in perfused rat heart. Am. J. Physiol. 276(2 Pt 2): H543-H552. PMID:9950856.
22. Markou, T., Cieslak, D., Gaitanaki, C., and Lazou, A. 2009. Differential roles of MAPKs and MSK1 signalling pathways in the regulation of c-Jun during phenylephrine-induced cardiac myocyte hypertrophy. Mol. Cell. Biochem. 322(1-2): 103-112. doi:10.1007/s11010-008-9945-8. PMID:19002563.
23. Martin, G., Duez, H., Blanquart, Ch., Berezowski, V., Poulain, Ph., Fruchart. J.C., et al. 2001. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J. Clin. Invest. 107(11): 1423-1432. doi:10.1172/JCI10852. PMID:11390424.
24. Merla, R., Ye, Y., Lin, Y., Manickavasagam, S., Huang, M.H., Perez-Polo, R.J., et al. 2007. The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation. Am. J. Physiol. Heart Circ. Physiol. 293(3): H1918-H1928. doi: 10.1152/ajpheart.00416.2007. PMID:17616749.
25. Michalik, L., and Wahli, W. 2006. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J. Clin. Invest. 116(3): 598-606. doi:10.1172/JCI27958. PMID:16511592.
26. Panagia, M., Gibbons, G.F., Radda, G.K., and Clarke, K. 2005. PPAR-α activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am. J. Physiol. Heart Circ. Physiol. 288(6): H2677-H2683. doi: 10.1152/ajpheart.00200.2004. PMID:15665064.
27. Paumelle, R., and Staels, B. 2008. Cross-talk between statins and PPARCα in cardiovascular diseases: clinical evidence and basic mechanisms. Trends Cardiovasc. Med. 18(3): 73-78. doi:10.1016/j.tcm.2008.01.001. PMID:18436144.
28. Paumelle, R., Blanquart, C., Briand, O., Barbier, O., Duhem, C., Woerly, O., et al. 2006. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-α via inhibition of the protein kinase C signaling pathway. Circ. Res. 98(3): 361-369. doi:10.1161/01.RES. 0000202706.70992.95. PMID:16397146.
29. Planavila, A., Laguna, J.C., and Vázquez-Carrera, M. 2005. Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-κB activation. Biochim. Biophys. Acta, 1687(1-3): 76-83. PMID:15708355.
30. Ravingerová, T., Matejíková, J., Neckář, J., Andelová, E., and Kolář, F. 2007. Differential role of PI3K/Akt pathway in the infarct size limitation and antiarrhythmic protection in the rat heart. Mol. Cell. Biochem. 297(1-2): 111-120. doi:10.1007/s11010-006-9335-z. PMID:17016676.
31. Razeghi, P., Young, M.E., Abbasi, S., and Taegtmeyer, H. 2001. Hypoxia in vivo decreases peroxisome proliferator-activated receptor α-regulated gene expression in rat heart. Biochem. Biophys. Res. Commun. 287(1): 5-10. doi:10.1006/bbrc.2001.5541. PMID:11549245.
32. Sambandam, N., Morabito, D., Wagg, C., Finck, B.N., Kelly, D.P., and Lopaschuk, G.D. 2006. Chronic activation of PPARα is detrimental to cardiac recovery after ischemia. Am. J. Physiol. Heart Circ. Physiol. 290(1): H87-H95. doi:10.1152/ajpheart.00285.2005. PMID:16155108.
33. Schäfer, A., Fraccarollo, D., Eigenthaler, M., Tas, P., Firnschild, A., Frantz, S., et al. 2005. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability. Arterioscler. Thromb. Vasc. Biol. 25(5): 1071-1077. doi:10.1161/01.ATV.0000161926.43967.df. PMID:15761193.
34. Shimizu, K., Aikawa, M., Takayama, K., Libby, P., and Mitchell. R.N. 2003. Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation, 108(17): 2113-2120. doi:10.1161/01.CIR.0000092949.67153.74. PMID:14517172.
35. Smeets, P.J.H., Planavila, A., van der Vusse, G.J., and van Bilsen, M. 2007. Peroxisome proliferator-activated receptors and inflammation: take it to heart. Acta Physiol. (Oxf.), 191(3): 171-188. PMID:17935522.
36. Szárszoi, O., Malý, J., Ošťádal, P., Netuka, I., Besík, J., Kolář, F., and Ošť ádal, B. 2008. Effect of acute and chronic simvastatin treatment on post-ischemic contractile dysfunction in isolated rat heart. Physiol. Res. 57(5): 793-796. PMID:18973424.
37. Tabernero, A., Schoonjans, K., Jesel, L., Carpusca, I., Auwerx, J., and Andriantsitohaina, R. 2002. Activation of the peroxisome proliferator-activated receptor α protects against myocardial ischaemic injury and improves endotheial vasodilatation. BMC Pharmacol. 2(1): 10. doi:10.1186/1471- 2210-2-10. PMID:11940253.
38. Takemoto, M., and Liao, J.K. 2001. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21(11): 1712-1719. doi:10.1161/hq1101.098486. PMID:11701455.
39. Tian, Q., Grzemski, F.A., Panagiotopoulos, S., and Ahokas, J.T. 2006. Peroxisome proliferator-activated receptor α agonist, clofibrate, has profound influence on myocardial fatty acid composition. Chem. Biol. Interact. 160(3): 241-251. doi:10.1016/j.cbi.2006.02.003. PMID:16540100.
40. Van Linthout. S., Riad, A., Dhayat, N., Spillmann, F., Du. J., Dhayat, S., et al. 2007. Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia, 50(9): 1977-1986. doi:10.1007/s00125-007-0719-8. PMID:17589825.
41. Wayman, N.S., Hattori, Y., McDonald, M.C., Mota-Filipe, H., Cuzzocrea, S., Pisano, B., et al. 2002. Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size. FASEB J. 16(9): 1027-1040. doi:10.1096/fj.01-0793com. PMID:12087064.
42. Wayman, N.S., Ellis, B.L., and Thiemermann, C. 2003. Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat. Med. Sci. Monit. 9(5): BR155-BR159. PMID:12761443.
43. Wolfrum, S., Grimm, M., Heidbreder. M., Dendorfer, A., Katus. H.A., Liao, J.K., and Richardt, G. 2003. Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase. J. Cardiovasc. Pharmacol. 41(3): 474-480. doi:10.1097/00005344-200303000-00017. PMID:12605027.
44. Yano, M., Matsumura, T., Senokuchi, T., Ishii, N., Murata, Y., Taketa, K., et al. 2007. Statins activate peroxisome proliferator-activated receptor γ through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ. Res. 100(10): 1442-1451. doi:10.1161/01.RES. 0000268411.49545.9c. PMID:17463321.
45. Yeh, C.H., Chen, T.P., Lee, C.H., Wu, Y.C., Lin, Y.M., and Lin, P.J. 2006. Cardiomyocytic apoptosis following global cardiac ischemia and reperfusion can be attenuated by peroxisome proliferator-activated receptor α but not gamma activators. Shock, 26(3): 262-270. doi:10.1097/01.shk.0000225863. 56714.96. PMID:16912651.
46. Yue, T.L., Bao, W., Jucker, B.M., Gu, J.L., Romanic, A.M., Brown, P.J., et al. 2003. Activation of peroxisome proliferator-activated receptor-α protects the heart from ischemia/reperfusion injury. Circulation, 108(19): 2393-2399. doi:10.1161/01.CIR.0000093187.42015.6C. PMID:14557369.
47. Zhou, R., Xu, Q., Zheng, P., Yan, L., Zheng, J., and Dai, G. 2008. Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat. Eur. J. Pharmacol. 586(1-3): 244-250. doi:10.1016/j.ejphar.2008.02.057. PMID:18384769.